EGFR Resisters on Twitter

EGFR Resisters Retweeted · Jill Feldman
@jillfeldman4
Patients face new realities (new dx & progression), have to make difficult Rx decisions w/little room for error but struggle w/whether survival is worth risk of side effects & how it will impact their/families life (physical, logistical, psycho/social, financial)
#WCLC22 #LCSM https://t.co/z65zys5gNL
View on Twitter
EGFRResisters photo
LUNGevity Foundation@LUNGevity
Thanks , Dr. Lavinia Magee @RoyalPapworth for bringing the patient perspectuve. And THANK YOU, @IASLC and #WCLC22 for including this imp topic and dedicating a plenary. And thank you @jillfeldman4 for reminding us tolerability is relative. #LCSM @EGFRResisters https://t.co/CBVGas7q9L
6
0
EGFR Resisters Retweeted · Jill Feldman
@jillfeldman4
Great talk Dr John Heymach #oligometastatic #nsclc challenges all to rethink #OMD: don't need to refine definition, we need to predict who benefits
Counting mets isn't enough, need multidimensional approach to include, biology, response to Rx &
% consolidatability.
#WCLC22 #LCSM https://t.co/LKQ7SaLTAa
View on Twitter
EGFRResisters photo
6
0
EGFR Resisters Retweeted · Jill Feldman
@jillfeldman4
Thank you for the great overview and tips @JFreemanDaily on the use of social media for patients and advocates!
#WCLC22 #LCSM https://t.co/5d6TrFKJbw
View on Twitter
Janet Freeman-Daily@JFreemanDaily
Use of Social Media and Communications Channels for #LungCancer Patient Advocacy #WCLC22  #LCSM https://t.co/KwNMkx6Wtl https://t.co/nFmohgqvnK
6
0
EGFR Resisters Retweeted · Jill Feldman
@jillfeldman4
A huge thank you to Dr Upal Basu-Roy for his careful attention to words & not using labels. Being defined by your smoking status is dehumanizing & demeaning to who we are as people.
Here's a link to @IASLC language guide https://t.co/FlnL660qIV
#LCSM #WCLC22 https://t.co/9Dt5EVZqH0
View on Twitter
EGFRResisters photo
LUNGevity Foundation@LUNGevity
Our own Dr Basu-Roy is back up at the podium talking about lung cancer in those w/out tobacco exposure: breaking it down by demographics & biology, driving it back that in those w/out exposure lung cancer will discriminate based on where you live & occupational exposure #wclc22 https://t.co/EqXzHiGRvr
7
0
EGFR Resisters Retweeted · Jill Feldman
@jillfeldman4
OS isn't the only impt endpoint for patients!
All trials, esp #SCLC, need
👉PROs
👉QOL endpt/compare UPFRONT/CONCURRENT #palliativecare
Dr Temel's data in #nsclc in 2010 shows ⬆️ BOTH QoL & survival
Sympts & AEs are tough- Pls help us live BETTER, not just longer!
#WCLC22 #LCSM https://t.co/8ukQkd3wQ0
View on Twitter
EGFRResisters photo
Stephen V Liu, MD@StephenVLiu
Long term results from KEYNOTE-604 (1L pembro + platinum + etoposide) from Dr. @charlesrudin. Missed OS endpoint, update with about 3.5y of f/u now at #WCLC22 https://t.co/CfWQwz3yYT
7
0
EGFR Resisters ·
@EGFRResisters
August newsletter is out! Latest EGFR Lung Cancer Research, patient advocacy and more. #lungcancer https://t.co/gu4XyCTKsO https://t.co/LIQrORgKK4
View on Twitter
EGFRResisters photo
5
13